Karen A. Dawes, current Board Chair at Repligen, stated, "Over the past two years, the Repligen Board has developed a leadership succession plan to provide for the Company's ongoing success. Elevating Tony Hunt to Executive Chair and promoting Olivier Loeillot to CEO ensures that we will continue to have a clear strategic vision and achieve our long-term goals. Tony has been an outstanding CEO and we thank him for his leadership and continued commitment to the Company. Olivier, given his exceptional experie ...

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the following June investor conferences. A live webcast of the conference presentations will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a ...

Sondra S. Newman Global Head of Investor Relations (781) 419-1881 investors@repligen.com William Blair's 44th Annual Growth Stock Conference being held in Chicago from June 4 – 6, 2024. Tony J. Hunt, Chief Executive Officer, is scheduled to present a company overview on June 5 at 12:00 p.m. CT. Jefferies' Global Healthcare Conference being held in New York from June 5 – 6, 2024. Olivier Loeillot, President and Chief Commercial Officer and Jason K. Garland, Chief Financial Officer, are scheduled to participa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in its Charter) For the transition period from ___________ to___________ Commission File Number 000-14656 REPLIGEN CORPORATION Delaware 04-2729386 (State or Other Ju ...

Repligen Corporation (NASDAQ:RGEN) Q1 2024 Results Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Sondra Newman - Head of Investor Relations Anthony Hunt - Chief Executive Officer Jason Garland - Chief Financial Officer Olivier Loeillot - President and Chief Commercial Officer Conference Call Participants Rachel Vatnsdal - J.P. Morgan Jacob Johnson - Stephens Inc. Puneet Souda - Leerink Partners Dan Arias - Stifel Conor McNamara - RBC Capital Markets Matt Larew - William Blair & Compan ...

Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2024 Financial Results WALTHAM, Mass., May 1, 2024 — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The company also reiterated its financial guidance for the full year 2024. Tony J. Hunt, Chief ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-2729386 (State or other jurisdiction of incorporat ...

Repligen Corporation (NASDAQ:RGEN) Q4 2023 Earnings Conference Call February 21, 2024 8:30 AM ET Company Participants Sondra Newman - Global Head, IR Anthony Hunt - CEO & Director Jason Garland - CFO Conference Call Participants Daniel Leonard - UBS Matthew Larew - William Blair & Company Puneet Souda - Leerink Partners Conor McNamara - RBC Capital Markets Matthew Hewitt - Craig-Hallum Capital Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Markets Daniel Arias - Stifel, Nicolaus & Company Rache ...

Revenue Performance - Q4 2023 revenue was $155.7 million, a decrease from $186.8 million in Q4 2022, while full-year 2023 revenue was $638.8 million, down from $801.5 million in 2022[8] - Total revenue for Q4 2023 decreased by 17% to $155.7 million compared to $186.8 million in Q4 2022, and full-year revenue declined by 20% to $638.8 million from $801.5 million in 2022[23] - Organic revenue growth (Non-GAAP) for Q4 2023 was -21%, reflecting a decline in base revenue excluding COVID-related and inorganic M&A impacts[25][26] - COVID-related revenue declined by 66% in Q4 2023 to $8.0 million from $23.8 million in Q4 2022, and by 77% for the full year to $32.2 million from $141.1 million in 2022[26] Profitability Metrics - Q4 2023 gross profit (GAAP) was $67.6 million, compared to $96.1 million in Q4 2022, with adjusted gross profit (non-GAAP) at $76.5 million[8] - Full-year 2023 net income (GAAP) was $41.6 million, down from $186.0 million in 2022, with adjusted net income (non-GAAP) at $98.4 million[8] - Q4 2023 loss per share (GAAP) was ($0.46), compared to earnings of $0.85 in Q4 2022, with adjusted earnings per share (non-GAAP) at $0.33[8] - Adjusted EBITDA (Non-GAAP) for Q4 2023 was $26.2 million, down from $49.1 million in Q4 2022, while full-year Adjusted EBITDA was $128.0 million compared to $246.9 million in 2022[31] - Net loss for Q4 2023 was $25.5 million, compared to a net income of $48.7 million in Q4 2022, with full-year net income dropping to $41.6 million from $186.0 million in 2022[23] - Adjusted net income (Non-GAAP) for Q4 2023 was $18.8 million, down from $39.1 million in Q4 2022, while full-year adjusted net income was $98.4 million compared to $188.6 million in 2022[28] - Adjusted earnings per share (Non-GAAP) for Q4 2023 was $0.33, down from $0.68 in Q4 2022, while full-year adjusted EPS was $1.75 compared to $3.28 in 2022[29] Cash and Investments - Cash, cash equivalents, and short-term investments at December 31, 2023, were $751.3 million, up from $623.8 million at the end of 2022[11] - Cash, cash equivalents, and marketable securities increased to $751.3 million as of December 31, 2023, up from $623.8 million at the end of 2022[24] Long-term Obligations - Long-term obligations rose significantly to $695.0 million as of December 31, 2023, compared to $209.8 million at the end of 2022[24] Guidance and Forecasts - FY 2024 revenue guidance is $620M - $650M, with a year-over-year change of (3%) - 2%[13] - FY 2024 adjusted EBITDA margin guidance is 18% - 19%[13] - Guidance for GAAP Net Income in 2024 ranges from $26.000 billion to $30.000 billion[35] - Adjusted Net Income (Non-GAAP) guidance for 2024 is projected between $80.000 billion and $84.000 billion[35] - GAAP Earnings Per Share (Diluted) guidance for 2024 is between $0.46 and $0.53[36] - Adjusted Earnings Per Share (Non-GAAP) guidance for 2024 is expected to be in the range of $1.42 to $1.49[36] Product Launches and Acquisitions - The company launched TangenX® SC, the industry's first holder-free, self-contained Tangential Flow Filtration (TFF) device[6] - The acquisition of Metenova AB contributed $5 million in revenue in Q4 2023, meeting expectations[6] Restructuring and Costs - Restructuring costs impacted Q4 2023 results with $8.2 million in adjustments, contributing to a total of $32.2 million for the full year[27][28] - Restructuring activities in Q4 2023 included inventory adjustments and manufacturing facility consolidation, with costs related to severance and employee-related expenses[39] R&D and SG&A Expenses - GAAP R&D Expense for Q4 2023 was $10.285 billion, a decrease of 7.5% compared to $11.113 billion in Q4 2022[33] - Adjusted R&D Expense (Non-GAAP) for Q4 2023 was $10.202 billion, down 7.4% from $11.021 billion in Q4 2022[33] - GAAP SG&A Expense for Q4 2023 increased to $57.512 billion, up 8% from $53.237 billion in Q4 2022[34] - Adjusted SG&A Expense (Non-GAAP) for Q4 2023 was $47.504 billion, an 8.1% increase from $43.947 billion in Q4 2022[34] Other Financial Items - Foreign currency gains on intercompany loans in Q4 2023 amounted to $7.743 billion, recorded under Other income (expenses), net[39] Order Strength - Q4 2023 book-to-bill ratio was 1.03, indicating continued order strength[5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to___________ Commission File Number 000-14656 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-2729386 (State or Othe ...